Drugs approved worldwide for the treatment of chronic hepatitis B (CHB) include interferons (IFNs) such as regular interferon and pegylated interferon (Peg-IFN), and nucleoside (acid) analogs (NA) such as lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine (LdT), and tenofovir (TDF). The former group of drugs can achieve HBeAg serological conversion in some patients, while the latter group can achieve effective inhibition of HBV replication in most patients, thus blocking or delaying disease progression. However, only a minority of patients can achieve the desired cure of HBsAg conversion. In the past few years, domestic and foreign scholars have conducted studies on the optimization and combination of existing NA and IFN treatments to improve the treatment of chronic hepatitis B and its related diseases. Careful collection of patient data in clinical practice, scientific evaluation of the stage of the patient’s disease, and rational application of these drugs can lead to significant improvements in treatment outcomes. As the goal of curing hepatitis C is achieved, scholars in various countries are actively developing new anti-HBV drugs that target each specific target of the hepatitis B virus replication cycle and infection link, and the development of hepatitis B therapeutic drugs has entered the fast track. I believe that in the next 5 to 10 years, a breakthrough in anti-HBV therapy is expected, and a cure for chronic hepatitis B will benefit the 93 million hepatitis B patients in China.?